The t(6;11)(q27;q23) is a recurrent chromosomal rearrangement that encodes the MLLAF6 fusion oncoprotein and is observed in patients with diverse hematologic malignancies. The presence of the t(6;11)(q27;q23) has been linked to poor overall survival in patients with AML. In this study, we demonstrate that MLL-AF6 requires continued activity of the histone-methyltransferase DOT1L to maintain expression of the MLL-AF6-driven oncogenic gene-expression program. Using gene-expression analysis and genome-wide chromatin immunoprecipitation studies followed by next generation sequencing, we found that MLL-fusion target genes display markedly high levels of histone 3 at lysine 79 (H3K79) dimethylation in murine MLL-AF6 leukemias as well as in ML2, a human myelomonocytic leukemia cell line bearing the t(6;11)(q27;q23) translocation. Targeted disruption of Dot1l using a conditional knockout mouse model inhibited leukemogenesis mediated by the MLL-AF6 fusion oncogene. Moreover, both murine MLL-AF6-transformed cells as well as the human MLL-AF6-positive ML2 leukemia cell line displayed specific sensitivity to EPZ0004777, a recently described, selective, small-molecule inhibitor of Dot1l. Dot1l inhibition resulted in significantly decreased proliferation, decreased expression of MLL-AF6 target genes, and cell cycle arrest of MLL-AF6-transformed cells. These results indicate that patients bearing the t(6;11)(q27;q23) translocation may benefit from therapeutic agents targeting aberrant H3K79 methylation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612861 | PMC |
| http://dx.doi.org/10.1182/blood-2012-11-465120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Characteristic Analysis of Adult Acute Myeloid Leukemia Patients with Gene Mutation].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
August 2024
Department of Hematology, Wuxi Second People's Hospital, Wuxi 214001, Jiangsu Province, China.
Objective: To investigate the incidence of gene mutation and its associated gene mutations in adult patients with acute myeloid leukemia (AML), and analyze its clinical characteristics.
Methods: Second-generation sequencing and Sanger sequencing were used to detect 51 gene mutations, and multiplex-PCR was used to detect 41 fusion genes from 451 newly diagnosed adult AML patients admitted to Affiliated Hospital of Jiangnan University, Changzhou Second People's Hospital, Wuxi People's Hospital and Wuxi Second People's Hospital from January 2017 to July 2022.
Results: Among 451 primary adult AML patients, the gene mutation was detected in 34 cases, and the mutation rate was 7.
Analysis of the clinical characteristics and prognosis of adult acute myeloid leukemia (none APL) with mutations.
Open Med (Wars)
November 2023
Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, 214122, China.
We discuss the clinical characteristics and prognostic significance of adult individuals with mutations who have developed acute myeloid leukemia (AML) (none acute promyelocytic leukemia). Next generation sequencing and Sanger sequencing were used to detect 51 gene mutations, and multiplex-PCR was used to detect 41 fusion genes from 232 adult AML patients retrospectively. About 7.
View Article and Find Full Text PDFSynergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia.
Exp Hematol Oncol
February 2023
Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, 87 Dingjiaqiao Street, Nanjing, 210009, China.
Background: More effective targeted therapy and new combination regimens are needed for Acute myeloid leukemia (AML), owing to the unsatisfactory long-term prognosis of the disease. Here, we investigated the synergistic effect and the mechanism of a histone deacetylase inhibitor, Chidamide in combination with Cladribine, a purine nucleoside antimetabolite analog in the disease.
Methods: Cell counting kit-8 assays and Chou-Talalay's combination index were used to examine the synergistic effect of Chidamide and Cladribine on AML cell lines (U937, THP-1, and MV4-11) and primary AML cells.
Multifunctional liposomal nanostructure-mediated siRNA/bortezomib co-delivery for SHARP1 knockdown in MLL-AF6 acute myeloid leukemia.
Biomater Adv
March 2022
Department of Micro-Nano Mechanical Science and Engineering, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan. Electronic address:
Acute myeloid leukemia (AML) has an extremely poor prognosis and high relapse and fatality rates. New therapeutic mechanisms for molecular targeted delivery are urgently needed to improve patient survival. In this study, we targeted the oncogenic transcription factor SHARP1 using multifunctional small interfering RNA (siRNA) and bortezomib (BTZ)-loaded cRGD-guided PEGylated cationic liposomal nanostructures to monitor their antileukemic activity in MLL-AF6 AML cells.
View Article and Find Full Text PDF[Clinical characteristics and prognosis of positive patients with acute myeloid leukemia].
Beijing Da Xue Xue Bao Yi Xue Ban
October 2021
Department of Hematology, Peking University International Hospital, Beijing 102206, China.
Objective: To investigate the clinical features and prognosis of acute myeloid leukemia (AML) patients with the mixed lineage leukemia () gene rearrangements () positive.
Methods: In the study, 11 patients who were newly diagnosed with positive AML were analyzed retrospectively, related literature was reviewed to clarify the clinical features and prognosis of positive patients.
Results: Among the 11 patients, there were 6 males and 5 females, with a median age of 36 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!